Major Highlights of the CAR-TCR Summit, Boston, 2016

Title:Major Highlights of the CAR-TCR Summit, Boston, 2016

Volume: 17 Issue: 10

Author(s): Vita Golubovskaya*, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu*

Affiliation:

• Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States

• Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States

Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.

Abstract: Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.

Cite this article as:

Golubovskaya Vita*, Berahovich Robert, Xu Shirley, Harto Hizkia and Wu Lijun*, Major Highlights of the CAR-TCR Summit, Boston, 2016, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (10) . https://dx.doi.org/10.2174/1871520617666170110151900